Skip to main content

Advertisement

Peer Review reports

From: Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Original Submission
26 Jul 2013 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
14 Feb 2014 Reviewed Reviewer Report - Arias Fernando
19 Mar 2014 Reviewed Reviewer Report - James A McCaul
1 Apr 2014 Author responded Author comments - Jean-Pascal Machiels
Resubmission - Version 3
1 Apr 2014 Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
Resubmission - Version 5
Submitted Manuscript version 5
3 Jun 2014 Author responded Author comments - Jean-Pascal Machiels
Resubmission - Version 6
3 Jun 2014 Submitted Manuscript version 6
Publishing
12 Jun 2014 Editorially accepted
28 Jun 2014 Article published 10.1186/1471-2407-14-473

You can find further information about peer review here.

Back to article page